Hepatocellular carcinoma (HCC), one of the most frequent tumors in the world, is included by the World Health Organization as a relevant public health problem in areas of high incidence as Africa and Southeast of Asia. In this review it will be discussed: a) the close relationship between HCC and hepatitis B virus (HBV), the more universal but not the single etiologic factor having other carcinogens and co-carcinogens involved with the origen of the tumor; b) the great variation in geographic distribution of this tumor, including that of Brazil where the incidence of HCC, including the new macroscopic classification according to the pattern of growth and general with liver cirrhosis in all countries where the tumor is diagnosed; d) some morphological aspects of HCC, including the new macroscopic classification according to the pattern of growth and general characteristics of small HCC; e) the clinical and biochemical aspects, calling attention to the evaluation of serum levels of alpha-fetoprotein, not always increased in patients with HCC, and the immage processing methods, specially ultrassonography, as methods for early diagnosis of HCC, being relevant in the follow-up of high risk patients (cirrhotics HBsAg (+]. Finally some comments are done about the therapeutic methods and perspectives of reduction in the incidence of the tumor with the use of vaccination against HBV infection.
Lymphoepitelioma is a particular form of undifferentiated carcinoma, characterized by a prominent lymphoid stroma, originally described in the nasopharynx. Lymphoid stroma-rich ...
Primary liver cancer is the fourth most common tumor worldwide. Hepatocellular carcinoma occurs mainly in the context of cirrhosis, hepatitis B or C virus infection, or nonalcoh...
Liver cancer remains a global health challenge, with an estimated incidence of >1 million cases by 2025. Hepatocellular carcinoma (HCC) is the most common form of liver cance...
Potential conflict of interest: Dr. Hwang received grants from Merck and Gilead. Dr. Chang advises Arbutus. Dr. Lok received grants from Gilead and Bristol‐Myers Squibb. Dr. Jon...
Aliment Pharmacol Ther 2011; 34: 274–285 Summary Background Non‐alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease, and its worldwide prevalence co...
Social media, news, blog, policy document mentions